Tafur GS, Abad ML, Montenegro M, Romero PR

Idioma: Español
Referencias bibliográficas: 28
Paginas: 315-317
Archivo PDF: 187.14 Kb.

RESUMEN

Antecedentes: c-kit es un receptor del factor de crecimiento que se expresa en diferentes tumores (leucemia mieloide crónica, neoplasias renales, etc.), incluido el sarcoma de Ewing/TNEP, lo que indica su posible función como marcador en la evolución tumoral y eventual tratamiento de estas neoplasias.
Objetivo: evaluar los tipos de sarcoma de Ewing positivos para CD117 (c-kit) y detectar a los pacientes que puedan beneficiarse con el tratamiento de inhibidores de la tirosina cinasa.
Material y método: estudio retrospectivo en pacientes con sarcoma de Ewing, en el Hospital Oncológico Solón Espinosa Ayala SOLCA de Quito, Ecuador, desde el 2003 hasta el 2007. Se revisaron bloques de tejido embebidos en parafina y se procesaron con la técnica habitual de inmunoperoxidasa con anticuerpos CD99 y CD117. La tinción se clasificó como leve (+), moderada (++) e intensa (+++).
Resultados: se registraron 16 pacientes, todos positivos para CD99, con lo que se corroboró el diagnóstico de Sarcoma de Ewing/TNEP; 11 (68.75%) resultaron positivos y 5 (31.25%) negativos para CD117. La tinción varió de leve (+) a intensa (+++); en todos los casos se localizó en el citoplasma o en membrana.
Conclusiones: los hallazgos son similares a los descritos en la bibliografía de otras partes del mundo (diferencia de 0.8%); por lo tanto, se piensa que un alto porcentaje de pacientes con estos tumores pueden beneficiarse con el tratamiento de inhibidores de la tirosina cinasa, específicamente sunitinib-imatinib.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F. Protein expression of KIT an gene mutation of C-kit and PDGIRs in Ewing sarcomas. Pathol Res Pract 2007; 203:127-34.

2. Scotlandi K, Manara M, Strammiello R, Landuzzi L, et al. Ckit receptor expressionin Ewing’s sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003;21:1952-60.

3. Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J. C kit expressing Ewing tumour cells are insensitive a imatinib mesylate (STI 571). Cancer Chemote Pharmacol 2002;50:167-9.

4. Konty U. Regulation of apoptosis and proliferation in Ewing sarcoma: oportunuties for targeted therapy. Hematol Oncol. 2006;1:14-21.

5. Burdach S. Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplant. Pediatric Transplant 2004;8(Supp l):67-82.

6. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use de imatinib en Ewing sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer INST 2002;94:1673-9.

7. Henrich M, Griffith D, Druker B, Wait C, et al. Inhibition of c-kit receptor tirosynkinase activity by STI, a selective tirosynekinase inhibitor. Blood 2000;96;925-932.

8. Kovar H. Ewing tumor biology: perpestives for innovative treatment approaches. Adv Exp Med Biol 2003;532:27-37.

9. Buchdunger E, Cioffi C, Law N, Stover D, et al. ABL proteintirosyne- kinase inhibitorSTI 571 inhibits in vitro signal transduction mediated by c kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.

10. Dabbs DJ. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: W.B. Saunders, 2006;pp:442-7.

11. Folpe A, Goldblum J, Rubin B, Shehata BM, et al. Morphologic and immunophenotypic diversity in Ewing family tumors. A study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-33.

12. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, et al. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing sarcoma. Eur J Cancer 2006;421:91-96.

13. Kontny U, Hammerle K, Klein R, Shayan P, et al. Sensitivity of Ewing sarcoma to trail induced apoptosis. Cell Death Differ 2001;8:506-14.

14. Llombart-Bosch A, Contesso G, Peydro-Olaya A. Ultrastructural study of 28 cases of Ewing sarcoma: typical and atypical forms. Cancer 1978;41:1362-73.

15. Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F. Protein expression of KIT an gene mutation of C-kit and PDGIRs in Ewing sarcomas. Pathol Res Pract 2007; 203:127-34.

16. Scotlandi K, Manara M, Strammiello R, Landuzzi L, et al. Ckit receptor expressionin Ewing’s sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003;21:1952-60.

17. Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J. C kit expressing Ewing tumour cells are insensitive a imatinib mesylate (STI 571). Cancer Chemote Pharmacol 2002;50:167-9.

18. Konty U. Regulation of apoptosis and proliferation in Ewing sarcoma: oportunuties for targeted therapy. Hematol Oncol. 2006;1:14-21.

19. Burdach S. Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplant. Pediatric Transplant 2004;8(Supp l):67-82.

20. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use de imatinib en Ewing sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer INST 2002;94:1673-9.

21. Henrich M, Griffith D, Druker B, Wait C, et al. Inhibition of c-kit receptor tirosynkinase activity by STI, a selective tirosynekinase inhibitor. Blood 2000;96;925-932.

22. Kovar H. Ewing tumor biology: perpestives for innovative treatment approaches. Adv Exp Med Biol 2003;532:27-37.

23. Buchdunger E, Cioffi C, Law N, Stover D, et al. ABL proteintirosyne- kinase inhibitorSTI 571 inhibits in vitro signal transduction mediated by c kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.

24. Dabbs DJ. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: W.B. Saunders, 2006;pp:442-7.

25. Folpe A, Goldblum J, Rubin B, Shehata BM, et al. Morphologic and immunophenotypic diversity in Ewing family tumors. A study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-33.

26. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, et al. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing sarcoma. Eur J Cancer 2006;421:91-96.

27. Kontny U, Hammerle K, Klein R, Shayan P, et al. Sensitivity of Ewing sarcoma to trail induced apoptosis. Cell Death Differ 2001;8:506-14.

28. Llombart-Bosch A, Contesso G, Peydro-Olaya A. Ultrastructural study of 28 cases of Ewing sarcoma: typical and atypical forms. Cancer 1978;41:1362-73.